Loading clinical trials...
Loading clinical trials...
A Prospective, Post-authorisation Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation, Including a Non-comparative Concurrent Reference Cohort
Conditions
Interventions
Imlifidase administered in the 20-HMedIdeS-19 (PAES) study
Best available treatment administered in the 20-HMedIdeS-19 (PAES) study
Locations
14
Austria
Medizinische Universitaet Wien
Vienna, Austria
Nephrology Clinic Vídeňská 1958/9
Prague, Czechia
Centre Hospitalier Universitaire (CHU) de Rouen - Hôpital de Bois-Guillaume
Bois-Guillaume, Normandy, France
Hôpital Necker - Enfants Malades
Paris, France
Azienda Ospedaliera di Padova
Padova, Italy
Azienda Ospedaliero - Universitaria di Parma
Parma, Italy
Start Date
July 3, 2023
Primary Completion Date
April 30, 2030
Completion Date
April 30, 2030
Last Updated
April 24, 2026
Lead Sponsor
Hansa Biopharma AB
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions